Australia markets closed

Cadrenal Therapeutics, Inc. (CVKD)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3980-0.0036 (-0.89%)
As of 09:57AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 6.58M
Enterprise value -1.80M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.86
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.22

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-72.65%
S&P500 52-week change 320.07%
52-week high 33.1400
52-week low 30.3600
50-day moving average 30.6318
200-day moving average 30.7441

Share statistics

Avg vol (3-month) 3437.99k
Avg vol (10-day) 3916.32k
Shares outstanding 516.01M
Implied shares outstanding 616.01M
Float 88.02M
% held by insiders 146.72%
% held by institutions 13.45%
Shares short (28 Mar 2024) 442.02k
Short ratio (28 Mar 2024) 40.47
Short % of float (28 Mar 2024) 40.49%
Short % of shares outstanding (28 Mar 2024) 40.26%
Shares short (prior month 29 Feb 2024) 47.17k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-102.62%
Return on equity (ttm)-780.59%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -7.63M
Net income avi to common (ttm)-8.36M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)8.4M
Total cash per share (mrq)0.52
Total debt (mrq)21.35k
Total debt/equity (mrq)0.28%
Current ratio (mrq)10.27
Book value per share (mrq)0.59

Cash flow statement

Operating cash flow (ttm)-3.53M
Levered free cash flow (ttm)-3.92M